James Shin Analyst PerformanceDirector & Senior BioPharma Analyst at Deutsche Bank AktiengesellschaftJames Shin is a stock analyst at Deutsche Bank Aktiengesellschaft in the medical sector, covering 5 publicly traded companies. Over the past year, James Shin has issued 8 stock ratings, including buy and hold recommendations. While full access to James Shin's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights James Shin's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings10 Last 1 YearsBuy Recommendations80.00% 8 Buy RatingsCompanies Covered5 Unique Companies Ratings Distribution10RatingsDistribution of strong buy, buy, hold, and sell ratings by James Shin.RatingPercentageCount Strong Buy0.0%0 ratings Buy80.0%8 ratings Hold20.0%2 ratings Sell0.0%0 ratingsOut of 10 total stock ratings issued by James Shin at Deutsche Bank Aktiengesellschaft, the majority (80.0%) have been Buy recommendations, followed by 20.0% Hold.Best & Worst CallsBest Call000.0%GILDFeb 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ60.0% of companies on NASDAQ3 companiesNYSE40.0% of companies on NYSE2 companiesJames Shin, an analyst at Deutsche Bank Aktiengesellschaft, currently covers 5 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical5 companies100.0%James Shin of Deutsche Bank Aktiengesellschaft specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE3 companies60.0%LARGE CAP PHARMA2 companies40.0% About James ShinJames Shin joined Deutsche Bank in April 2023 as a Director and Senior BioPharma analyst. James was most recently at Wells Fargo where he covered SMid Cap Oncology focused Biotech stocks. Prior to that, James was an associate on the Biotech team at Citi. James earned his undergraduate degree from the University of Maryland in Chemistry & Life Sciences and started his science career at Johns Hopkins as a Research Specialist from 2009-2016.Follow on LinkedIn James Shin's Ratings History at Deutsche Bank Aktiengesellschaft Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsSTROSutro Biopharma3/25/2026Boost Price Target$24.20$55.00Buy$0.0000.00% ROILLYEli Lilly and Company3/6/2026Reiterated Rating$984.76$1,285.00Buy$0.0000.00% ROIMRKMerck & Co., Inc.2/13/2026Upgrade$119.25$150.00Buy$0.0000.00% ROILLYEli Lilly and Company2/9/2026Boost Price Target$1,057.10$1,285.00Buy$0.0000.00% ROILLYEli Lilly and Company12/17/2025Boost Price Target$1,071.35$1,200.00Buy$0.0000.00% ROIMRKMerck & Co., Inc.11/18/2025Boost Price Target$96.73$111.00Hold$0.0000.00% ROILLYEli Lilly and Company8/11/2025Lower Price Target$640.50$900.00Buy$0.0000.00% ROIIMTXImmatics5/28/2025Initiated Coverage$5.05$10.00Buy$0.0000.00% ROIMRKMerck & Co., Inc.2/18/2025Downgrade$83.01$105.00Hold$000.0000.00% ROIGILDGilead Sciences2/18/2025Upgrade$104.08$120.00Buy$000.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageMorgan StanleyJefferies Financial GroupStifel NicolausOppenheimerBerenberg BankRoth MkmWall Street ZenUBS GroupCitigroupBarclaysWells Fargo & CompanyRoyal Bank Of CanadaJPMorgan Chase & Co.The Goldman Sachs GroupTD Cowen Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
